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Abstract:  
Targeted inhibition of Anaplastic Lymphoma Kinase (ALK) is a successful approach for the 
treatment of many ALK-aberrant malignancies, however the presence of resistant mutations 
necessitates both the development of more potent compounds and pharmacodynamic 
methods with which to determine their efficacy.  We describe immunoassays designed to 
quantitate phosphorylation of ALK, and their use in preclinical models of neuroblastoma, a 
pediatric malignancy in which gain-of-function ALK mutations predict a poor overall 
outcome to conventional treatment.  Validation of the immunoassays is presented using a 
panel of neuroblastoma cell lines and evidence of on-target ALK inhibition provided by 
treatment of a genetically engineered murine model of neuroblastoma with two clinical ALK 
inhibitors, crizotinib and ceritinib, highlighting the superior efficacy of ceritinib.  
 
1. Introduction 
The rapid development of targeted therapeutics against Anaplastic Lymphoma Kinase (ALK) 
has already resulted in significant changes to the up-front treatment of patients with ALK-
rearranged non-small cell lung cancer (NSCLC) (Camidge et al., 2012), and a current aim is 
to bring these personalized therapies to the benefit of childhood cancer patients, including 
those with neuroblastomas that harbor point mutations of ALK (Chen et al., 2008; George et 
al., 2008; Janoueix-Lerosey et al., 2008; Mosse et al., 2008).  The broad range of ALK 
mutations found either as a secondary resistance mechanism to ALK inhibition in NSCLC or 
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as a primary resistance mechanism in neuroblastoma necessitates thorough interrogation of 
the ability of individual compounds to inhibit ALK phosphorylation and subsequent survival 
signaling downstream of ALK, enabling the rapid translation of the most promising 
compounds from the laboratory to clinical trials (Bresler et al., 2014; Bresler et al., 2011).  To 
achieve this, highly relevant preclinical models should be coupled with accurate methods to 
report pharmacodynamic responses.  
 
We have therefore developed sensitive immunoassays to detect and quantitate the expression 
of total ALK protein and phosphorylated forms of ALK using the mesoscale technology 
(MSD®) platform.  This format allows for the development of assays that are appropriate for 
both in vitro and in vivo studies, and MSD® assays are already routinely incorporated into 
clinical studies in order to measure pharmacodynamic end points (Basu et al., 2015).  We 
sought to validate our ALK immunoassays using both neuroblastoma cells lines and tumor 
tissue from the Th-ALKF1174L/MYCN transgenic model, which has previously demonstrated 
the inadequacy of the first generation ALK inhibitor, crizotinib, to elicit therapeutic 
responses in ALK F1174L-driven neuroblastomas (Berry et al., 2012).   
Our results demonstrate the successful application of MSD® immunoassays to measure ALK 
and phosphorylated ALK as pharmacodynamic biomarkers following treatment with small 
molecule ALK inhibitors both in vitro and in ex vivo tissue.  We show that in addition to 
autophosphorylation of ALK at Y1278 and Y1604, following the fate of phosphorylated 
ALK at Y1586 also provides a marker of active ALK levels. 
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2. Materials and Methods 
 
2.1 Cell lines 
Neuroblastoma cell lines and HeLa cells were obtained from the American Type Culture 
Collection, CLB-GA was a gift from V. Combaret (Lyon), and were shown to be 
Mycoplasma-free using a PCR-based assay (Minerva Biolabs).  The Ba/F3 ALK F1174L 
cells were a gift from Dr Rani George (Boston, USA) and were transduced as described 
previously (George et al., 2008).  Cells were cultured in RPMI 1640 media supplemented 
with 2mM glutamine (Gibco), 1X MEM non-essential amino acids and 10% FCS (Gibco) 
and grown at 37ºC with 5% CO2 in a humidified incubator. 
 
2.2 Drug treatments 
Cell lines were treated at 50-70% confluency at the indicated drug concentrations or with 
DMSO at a concentration that matched the greatest DMSO for the drug-treated cells.  
Crizotinib and ceritinib were purchased from Shanghai Haoyuan Chemexpress Company.  
 
2.3 GI50 determination 
In order to calculate the half maximal growth inhibitory concentration (GI50) of individual 
compounds, neuroblastoma tumor cells were seeded into 96-well plates in a total volume of 
100µl and allowed to attach overnight.  Compound (dissolved in DMSO) was added to wells 
in six replicates of 100µl, across a concentration gradient including a DMSO-only control, 
the next day.  The cells were exposed to drug for 72 hours.  Thereafter, the cell number in 
treated versus control wells was estimated after cell fixation with 10% trichloroacetic acid 
and staining with sulforhodamine B in 1% acetic acid.  The GI50 was calculated as the drug 
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concentration that inhibits cell growth by 50% compared with control growth, according to 
non-linear regression analysis, using Graphpad Prism. 
 
2.4 Preparation of protein lysates 
Cell lines were harvesting by scraping, spun at 500xg for 5 minutes, washed once in 
phosphate-buffered saline and the cell pellets resuspended in CHAPS lysis buffer (50mM 
Tris-HCl pH 8.0, 1mM EDTA, 150mM NaCl, 1% CHAPS, 0.2mM PMSF, 1:50 Phosphatase 
Inhibitor Cocktail 2 and 3 (Sigma-Aldrich), 1:100 Protease Inhibitor Cocktail (Sigma-
Aldrich)).  Frozen tissue samples were homogenized in CHAPS lysis buffer prepared as for 
cell lysates.  After incubation for 30 minutes on ice, lysates were spun at 16,000xg for 15 
minutes and the supernatant collected.  Protein concentrations were determined using BCA 
protein assay (Thermo Scientific) by comparison with bovine serine albumin standards. 
 
2.5 ALK Meso Scale Discovery® immunoassays 
Multi-array 96-well plates (Meso Scale Discovery) were coated overnight at 4°C with 
0.5µg/ml mouse total ALK antibody (Clone 31F12, Cell Signaling Technology) diluted in 
50mM carbonate buffer.  Plates were washed 5X in wash buffer (0.1% tween20 in Tris-
buffered saline) and incubated for 1 hour with blocking buffer (5% BSA in wash buffer).  
After washing, samples were added with cell lysates being diluted to 20 µg/well (in vitro) or 
30 µg/well (in vivo) in 1X Tris Lysis Buffer (Meso Scale Discovery) or recombinant ALK 
protein (Thermo Fisher Scientific) diluted in phosphate-buffered saline, and incubated 
overnight at 4°C.  After washing, plates were then incubated for 1 hour with the appropriate 
antibody (0.4µg/ml total ALK D5F3, 0.2µg/ml pY1278 ALK D59G10, 0.4µg/ml pY1586 
ALK 3B4, 0.2µg/ml pY1604 ALK D96H9 or 0.2µg/ml phospho-tyrosine P-Tyr-1000, all 
purchased from Cell Signaling Technology), washed and incubated for a further 1 hour with 
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0.5µg/ml anti-rabbit SULFO-tag antibody.  The plates were washed, 2X Read Buffer T 
(Meso Scale Discovery) added to wells and electrochemiluminescence counts read using a 
MSD SECTOR Imager 6000. 
 
2.6 Immunoblotting 
Western blotting of 20ug of denatured lysates was carried out using pre-cast 4-12% Bis-Tris 
gels in 1x MOPS running buffer (Invitrogen).  A pre-stained molecular weight marker was 
loaded alongside the experimental samples (Invitrogen).  The gels were transferred to PVDF 
membranes at 30V for 3 hours, or at 0.05mA overnight.  The membranes were blocked for 
one hour in 5% (w/v) non-fat dry milk in tris-buffered saline with 0.1% Tween20 (TBST), 
and then incubated with primary antibody overnight at 4°C in 2.5% milk TBST (ALK, 
pY1278 ALK, pY1604 ALK, pY1586 ALK (all equivalent to the respective MSD® 
immunoassay), ERK1/2, pERK1/2, Akt, pAkt, GAPDH all from Cell Signaling).  Membranes 
were incubated with the appropriate horseradish peroxidase-linked secondary antibody and 
proteins visualized using electrochemical luminescence  (ECL plus) (Amersham Biosciences) 
detection system on a LAS-3000 Imaging System (Fujifilm Life Science).  Quantification of 
blots was performed by densitometry using ImageJ software analysis. 
 
2.7 Immunoprecipitation 
Cells lysates were subjected to pre-clearing before direct incubation with the antibody of 
interest (ALK; IgG) for an hour at 4oC.  Protein G beads were added to the lysate and 
incubated overnight at 4oC.  The next day, the samples were spun down for 30 seconds at 4oC 
and the supernatant was discarded.  The bead pellet was washed 5 times with lysis buffer, 
before denaturing by heating to 95oC for 5 minutes in SDS sample buffer.  
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2.8 Mouse models 
All experiments, including the breeding of transgenic animals, were performed in accordance 
with the local ethical review panel, the UK Home Office Animals (Scientific procedures) Act 
1986, the ARRIVE (Animal Research: Reporting of In Vivo Experiments) guidelines 
(Kilkenny et al., 2010) and the UK NCRI guideline (Workman et al., 2010).  Th-
ALKF1174L/MYCN tumor-bearing animals were enrolled into therapeutic trials when their 
abdominal tumors reached 5mm in diameter according to palpation.  Volumetric MRI was 
performed as previously described (Jamin et al., 2013), with each animal under-going 
imaging on day 0 and day 7.  The tumor volume at each time point was then calculated.  For 
in vivo oral dosing on day 1 - 7, crizotinib was dissolved in sterile water with 10% Tween 20.  
Ceritinib was dissolved into 0.5% methylcellulose, 0.5% Tween 80 with sterile water.  Two 
hours following the final dose of either compound, tumor tissue was excised and snap frozen 
prior to analysis. 
 
3. Results 
3.1 Detection of recombinant ALK (rALK) protein with immunoassays 
Using the MSD® platform we optimized immunoassays to detect phosphorylated or total 
ALK protein.  Confirmation of the ability of the assays to detect ALK or phosphorylated 
ALK species was sought through the use a kinase active recombinant ALK (rALK) protein 
(figure 1).  Using a titrating amount of rALK, we found that pan-pY ALK, pY1278 ALK, 
pY1586 ALK, pY1604 ALK or total ALK were detected in a linear fashion in each assay 
(figure 1.A).  The reproducibility of the assays to detect rALK was assessed both within a 
single experiment (figure 1.B) and across at least three independent experiments (figure 1.C).  
In all cases the intra-assay percentage coefficient of variation for pY1278, pY1604 and total 
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ALK was less than 2.4%, 6.2% and 6.2% respectively. In four out of five samples for the pY 
assay and the pY1586 assay the coefficient of variation was less than 2.5% and 5.4% 
respectively. The inter-assay variability was less than 30% in all assays, indicating high 
reproducibility of the assay signals. 
 
3.2 Immunoassays quantitate ALK and phosphorylated ALK forms in neuroblastoma cell 
lines 
Gain-of-function mutations of ALK, which lead to constitutive ALK phosphorylation, are 
known to contribute to the aggressive nature of pediatric neuroblastoma tumors, and therefore 
the detection of ALK activity in available neuroblastoma cell lines is of increasing 
importance.  We employed a panel of these cell lines harboring either one of the two most 
frequent ALK mutations (F1174L or R1275Q), or wild-type ALK, and assessed the total and 
phosphorylated abundance of ALK by immunoblotting, in addition to pathways downstream 
of ALK (figure 2.A).  When compared to the Ba/F3 transduced cell lysates, it was apparent 
that detection and therefore quantification of phosphorylated ALK is challenging in the 
neuroblastoma cell panel by western blotting as bands were only clearly visible for pY1278 
and pY1586 ALK in CLB-GA and LAN-5 lysates.  Phosphorylated Akt and phosphorylated 
ERK 1/2 signals were detected more strongly in CLB-GA and LAN-5 again, as well as in 
three out of the four ALK F1174L cell lines, excluding Kelly cells.  However, analyzing the 
same cell lysates in the ALK immunoassays we developed, showed detectable levels of 
pY1278, pY1586, pY1604 and total ALK in all the neuroblastoma cell lines tested, whereas 
no signals were obtained for HeLa cell lysate in any of the ALK assays consistent with the 
lack of ALK expression (figure 2.B).  When the levels of phosphorylated ALK in the 
neuroblastoma cell lines were normalized to total ALK signals from the immunoassays and 
compared with densitometry of the immunoblots, there was a positive correlation that was 
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statistically significant for the total ALK and pY1278 and pY1586 ALK assays, and although 
not significant, a positive trend between densitometry and immunoassay for the detection of 
pY1604 ALK was seen (figure 2.C).  Furthermore, upon immunoprecipitation of ALK and 
detection of pan-pY from the same lysates (figure 2.D), there was a stronger pY signal 
obtained for the two cell lines harboring the R1275Q ALK mutation (CLB-GA and LAN-5).  
This finding is consistent with CLB-GA and LAN-5 cell lysates giving the highest signals out 
of the cell line panel in the pY1278, pY1586 and pY1604 ALK assays (figure 2.B) and the 
pY-ALK MSD® assay (figure 2.E).  Together these data indicate that the ALK immunoassays 
can be used to characterize basal levels of ALK activity in neuroblastoma cells in a more 
quantitative manner and with greater sensitivity than immunoblotting.  
 
3.3 ALK immunoassays quantify the dose- and time- dependent response of neuroblastoma 
cell lines to therapeutic ALK inhibition 
To further assess the ability of the phospho-ALK MSD assays to measure changes in ALK 
activity, we made use of two clinical small molecule ALK inhibitors, crizotinib and ceritinib.  
Crizotinib was less successful against ALK F1174L neuroblastomas in clinical trial, but 
showed efficacy in the treatment of ALK R1275Q neuroblastomas (Mosse et al., 2013).  
Ceritinib is a second-generation ALK inhibitor, currently being evaluated in pediatric clinical 
studies.  We used two neuroblastoma cell lines to compare crizotinib and ceritinib treatment 
in a dose-dependent and time-dependent manner using the total ALK, pY ALK, pY1278, 
pY1604 and pY1586 ALK immunoassays (figure 3).  The drug concentrations were decided 
using the GI50 values for each compound (table 1).  Kelly cells (ALK F1174L) demonstrated 
a similar dose response to both drugs (figure 3.A) with inhibition of ALK phosphorylation at 
sub-GI50 concentrations, and this similarity was reflected in the accompanying immunoblot 
(pY1604 and pY1278 immunoblots did not detect bands and are therefore not included).  
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CLB-GA cells (ALK R1275Q) (figure 3.B) were more sensitive to treatment with ceritinib 
than crizotinib, with over 50% inhibition of phosphorylation seen with all phospho-ALK 
assays at 10nM ceritinib.  This result is also seen in the accompanying immunoblot (pY1604 
immunoblot did not detect bands and is therefore not included) (figure 3.B).  In both cell 
lines, loss in pY1586 ALK signal follows the pattern of decreasing pY ALK, pY1604 ALK 
and pY1278 ALK (CLB-GA only) with ALK inhibition and a reduction in band intensity in 
the accompanying immunoblots for pY1278 ALK.  Although, ALK phosphorylation was 
inhibited at sub-GI50 concentrations of crizotinib or ceritinib, inhibition of signaling pathways 
downstream of ALK, such as AKT and ERK1/2, were not inhibited until higher 
concentrations at 3 hours treatment (immunoblots in figure 3.A and 3.B).  The results of the 
dose-response experiments led to the choice of drug concentrations to be used in the 
subsequent time course experiments, as the dose that led to a percentage of DMSO treated at 
near 20% phosphorylated ALK.   
 
There was a rapid decrease in the phosphorylated / Total ALK ratio (P/T ratio) in Kelly cells 
(figure 3.C) (graphed as percentage of zero hours control sample) following treatment of the 
cells with either crizotinib or ceritinib.  This effect was sustained for 24 hours and is reflected 
in the accompanying immunoblots of the same lysates, where sustained inhibition of 
phosphorylated ERK1/2, a downstream effector of ALK, is also apparent following treatment 
with either compound.  Subtle inhibition of phosphorylation of Akt at S473 was also evident 
following treatment of Kelly cells with crizotinib or ceritinib.  Treatment of CLB-GA cells 
(figure 3.D) with either crizotinib or ceritinib also resulted in a rapid reduction in P/T ALK 
ratio from 10 minutes treatment; an effect that was also sustained for the entire 24 hour time 
course.  At 50nM there was some evidence that the downstream effectors of ALK were 
differentially affected following treatment with either compound.  De-phosphorylation of Akt 
A
cc
ep
te
d 
A
rt
ic
le
Molecular Oncology (2017) © 2017 The Authors. Published by FEBS Press and John Wiley 
& Sons Ltd. 
at S473 occurred more rapidly after treatment of the cells with crizotinib, however, although 
treatment with either compound gave rise to a loss of ERK1/2 phosphorylation quickly, this 
effect was transient and not sustained for the duration of the experiment. Together our results 
indicate that a sustained dephosphorylation of ALK at multiple phosphorylation sites by both 
crizotinib and ceritinib can be detected quantitatively by immunoassay in neuroblastoma cell 
lines with ALK mutations at F1174L or R1275Q.          
 
3.4 Treatment of Th-ALKF1174L/MYCN tumor-bearing animals demonstrates increased 
efficacy of ceritinib over crizotinib and a greater pharmacodynamic response  
Finally, we tested frozen tissue specimens from Th-ALKF1174L/MYCN animals (in which 
spontaneous tumors arise, driven by co-expression of the human ALKF1174L and human MYCN 
transgenes), which had been treated with either crizotinib or ceritinib for seven days.  
Treatment of animals with ceritinib (100mg/kg/day) results in delayed growth or tumor 
regression (established using non-invasive MRI volumetric measurements (figure 4.B depicts 
representative images)), compared to delayed growth only following treatment with crizotinib 
(100mg/kg/day) (figure 4.A). The quantitation of pY1586 ALK and total ALK by 
immunoassay is shown next to the corresponding immunoblots (figure 4.C and 4.D). The 
ratio of pY1586 to total ALK revealed a mean decrease to 0.34 following crizotinib treatment 
versus 0.17 following ceritinib treatment (each normalized to the mean of their respective 
vehicle controls) (figure 4.E), indicating a larger pharmacodynamic effect with ceritinib, 
consistent with the tumor volume data (figure 4.A).  Our results suggest that these 
immunoassays are suitable for the quantification of ALK as a biomarker following targeted 
therapy in vivo. 
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4. Discussion 
In this report we have validated immunoassays to detect ALK and phosphorylated ALK in 
vitro, successfully applied them to an in vivo model of neuroblastoma and demonstrated a 
quantitative difference in on-target pharmacodynamic changes between a first and second 
generation ALK inhibitor. 
 
To date the majority of studies investigating the mechanism of activation and 
phosphorylation of ALK utilize oncogenic ALK fusion proteins, such as NPM-ALK.  
Activation of full length ALK has been shown to result in the phosphorylation of Y1278 
alongside Y1282 and Y1283, which lie in the Y’Ras’YY autophosphorylation motif within 
the activation loop (Tartari et al., 2008).  Y1604 is found at the C-terminal tail of the 
receptor, and has been reported to be important for transformation activity and docking of 
phospholipase Cy in studies on NPM-ALK.  Subsequently Y1604 and Y1586 were together 
identified as tyrosine sites phosphorylated following ALK activation in a phosphoproteomics 
study of full length ALK (Sattu et al., 2013), and the detection of dephosphorylation at 
Y1586 by our immunoassay, following treatment with ALK inhibitors, confirms the role of 
this phosphorylation site in the constitutive activity of ALK. 
 
Our panel of neuroblastoma cell lines harbor either the ALK F1174L, or the ALK R1275Q, 
mutation or express wild-type ALK only and therefore represent two of the three hotspots of 
ALK mutation sites in neuroblastoma tumors (Bresler et al., 2014).  Our cross-comparison of 
immunoblots with the ALK immunoassays reveals strong correlation of the detection of total 
ALK and two out of three ALK phosphorylation sites (figure 2, section 3.2).  The 
immunoprecipitation of ALK and detection of pY furthermore reflects the results from the 
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pY ALK immunoassay.  Measurement of phosphorylated ALK by immunoassay has several 
advantages over western blotting such as greater quantitative power and higher throughput 
analysis of samples. The MSD® platform we used also provides superior sensitivity and a 
much greater dynamic range in which to detect changes in ALK activity. 
 
Interestingly, by analyzing a neuroblastoma cell line panel we found that cells with the ALK 
R1275Q mutation had the strongest ALK phosphorylation signals.  R1275 accounts for 43% 
of ALK mutations in neuroblastoma, yet mutations at the F1174 locus (accounting for 30% of 
ALK mutations) are reported to have the strongest effect on non-phosphorylated ALK 
tyrosine kinase domain in vitro (Bresler et al., 2014).  It is possible that ALK kinase activity 
is different in a whole cell environment and acclimatization to cell culture conditions alters 
the dominant cell signaling pathways and accounts for this discrepancy between purified 
mutated ALK tyrosine kinase domain experiments and our cell-based approaches.  
Furthermore, we show that dephosphorylation at the pY1586 site closely followed 
dephosphorylation at the pY1278 and pY1604 autophosphorylation sites upon ALK 
inhibition, and therefore phosphorylation of ALK at any of these three sites could be used as 
pharmacodynamic biomarkers for ALK activity. 
 
Crizotinib and ceritinib are both under clinical evaluation for the treatment of ALK-positive 
neuroblastomas with genetic ALK alterations, and our immunoassays allow for a direct 
pharmacodynamic preclinical comparison of the two compounds (Mosse et al., 2013).  The 
observation that ceritinib has a lower GI50 in CLB-GA than crizotinib is supported by the 
results of the immunoassay in these cells, where we see inhibition of ALK phosphorylation 
following treatment with ceritinib at lower concentrations to crizotinib (figure 3, section 3.3).  
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Downstream signaling mediators of ALK include the PI3K (phosphatidylinositol 3-
kinase)/Akt, The JAK/STAT (Janus activated kinase/signal transducer and activator of 
transcription) and Ras/Raf/MEK/ERK1/2 pathways (Berry et al., 2012; Sattu et al., 2013; 
Umapathy et al., 2014).  The immunoblots show a return of signal for phosphorylated 
ERK1/2 after one hour of crizotinib treatment, but as the dephosphorylation of ALK at all 
phosphorylation sites remained evident for 24 hours according to the immunoassay results, it 
could suggest that feedback mechanisms are activated or that cellular switching to up-
regulate alternative signaling pathways occurs.  However, our immunoassays were able to 
specifically define the minimum concentration of inhibitor required to produce ALK 
dephosphorylation, and to demonstrate over what time period this occurs.  The ability of our 
immunoassays to robustly quantify these ALK inhibitor characteristics in biological models 
will therefore provide valuable information to both their pre-clinical and clinical evaluation 
in defining active doses and optimum treatment schedules.   
 
To assess the utility of the pY1586 ALK immunoassay to measure pharmacodynamic 
changes in an animal model treated with crizotinib or ceritinib, ALK phosphorylation status 
was quantified in ex vivo tumor tissue (figure 4, section 3.4).  The transgenic Th-
ALKF1174L/MYCN model develops spontaneous abdominal neuroblastomas in an 
immunocompetent background.  The dephosphorylation of ALK detected by the 
immunoassay in this context by both compounds suggests that delivery of the drug results in 
on-target inhibition of ALK in tumors.  Moreover, the magnitude of dephosphorylation 
reflected the volumetric response of tumors to treatment with either inhibitor, and reinforced 
the conclusion that ceritinib is superior to crizotinib in the inhibition of ALK F1174L in vivo.  
The sensitivity and quantitative power of the immunoassay to detect these changes in 
phosphorylation in this context could be seen as a prelude for the future development of this 
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assay as a tool to measure ALK activity as a clinical biomarker.  In particular we aim that our 
immunoassays could be embedded into pediatric clinical studies of ALK inhibitors in which 
biopsies at relapse are being encouraged.  In this way, at the very least we would be able to 
correlate an observed clinical response to a targeted inhibitor with knowledge of the extent of 
ALK expression measured in the latest available biopsy.  Additionally, these immunoassays 
will play a key role in the evaluation of ALK-targeted agents in the panel of patient-derived 
xenografts to be generated within the European Innovative Medicines Initiative consortium.  
  
5. Conclusions 
Several inhibitors of the tyrosine kinase ALK have been evaluated in clinical studies for adult 
cancer patients, and the inherent resistance of the ALK mutations found in pediatric 
neuroblastomas necessitates thorough preclinical investigation of the available compounds.  
We have developed and validated quantitative immunoassays to measure total ALK and 
phosphorylated ALK at biologically relevant phosphorylation sites.  These assays will 
support the preclinical decision making process in the evaluation of therapeutic ALK 
inhibitors using both in vitro and in vivo models. 
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Table 1. 72-hour GI50 of crizotinib or ceritinib in neuroblastoma cell lines (nM).  
Mean±SD from 3 independent repeats. 
 
Cell Line Crizotinib Ceritinib 
SH-SY5Y 480.6 ± 93.0 82.0 ± 25.4 
LAN-1 236.6 ± 9.8 46.8 ± 36.3 
SK-N-SH 3059.5 ± 272.2 1311.5 ± 252.4 
Kelly 432.4 ± 28.6 542.4 ± 62.2 
CLB-GA 167.6 ± 48.3 43.4 ± 7.3 
LAN-5 132.0 ± 22.8 47.3 ± 6.3 
IMR-32 511.7 ± 29.1 1203.8 ± 386.7 
 
Figure Captions 
Figure 1. Immunoassays to quantitate phosphorylated and total ALK protein.  
(A) Titration of recombinant ALK protein (rALK) in MSD® assays to quantify pan-phospho-
tyrosine ALK, phospho-Y1278 ALK, phospho-Y1586 ALK, phospho-Y1604 ALK and total 
ALK protein levels.  Mean±SD from ≥3 independent repeats.  R squared values for linear 
regression from each of the assays is indicated. Assay reproducibility was assessed by (B) 
intra-assay variability calculated across triplicate wells of each ALK MSD® assay with 
increasing concentrations of recombinant ALK protein (same as A) and (C) inter-assay 
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variability calculated across from ≥3 independent repeats using increasing concentrations of 
recombinant ALK protein (same as A) and is presented as percentage coefficient of variation 
(CV). 
 
Figure 2. Basal ALK activity in neuroblastoma cell lines.   
(A) Immunoblots of lysates from neuroblastoma cell line panel, including lysate from Ba/F3 
ALK F1174L as a positive control for ALK expression and lysate from Hela cells as negative 
control for ALK expression.  Arrows indicate ALK band of interest at 220KDa.  (B) 
Quantitation of phospho-Y1278 ALK, phospho-Y1586 ALK, phospho-Y1604 ALK and total 
ALK protein levels in a cell line panel using immunoassays.  Mean±SD from ≥3 biological 
repeats. (C) Correlation of MSD® ECL counts with quantitation of total ALK (tALK) (P = 
0.0033**) and phospho-ALK (pY1278 ALK P =<0.0001***; pY1586 ALK P = 0.0012**; 
pY1604 ALK P = ns (not significant)) immunoblots for neuroblastoma cell lysates.  r values 
for Pearson Rank Correlation of each graph are indicated. (D) Immunoprecipitation of total 
ALK from the same neuroblastoma cell line panel lysates (as in (A)), to allow assessment of 
pan-phospho-tyrosine ALK status. (E) Quantitation of pan-phospho-tyrosine ALK, in a cell 
line panel by immunoassay.  Mean±SD from ≥3 biological repeats.    
   
Figure 3. Dose response and time course comparison of ALK inhibition by crizotinib or 
ceritinib.   
Dose response in Kelly (A) and CLB-GA (B) neuroblastoma cells with 3 hours treatment of 
crizotinib or ceritinib.  Phosphorylated and total ALK levels were quantified by MSD® 
immunoassays and mean±SD from 3 independent repeats are shown.  Corresponding 
immunoblots of Kelly and CLB-GA cell lysates following treatment with either crizotinib or 
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ceritinib are shown below as indicated.  Vertical dashed lines indicate GI50. Time course 
treatment of Kelly cells (C) with crizotinib or ceritinib (both 200nM) and CLB-GA cells (D) 
with crizotinib or ceritinib (both 50nM).  Phosphorylated and total ALK levels were 
quantified by MSD® immunoassays (3 independent repeats) and the Phosphorylated ALK / 
total ALK ratio as a % of untreated is plotted.  Corresponding immunoblots of Kelly and 
CLB-GA cell lysates following treatment with either crizotinib or ceritinib are shown below 
as indicated.      
 
Figure 4. Tumor volume measurement and MSD® immunoassay quantitation of Th-
ALKF1174L/MYCN tumors following treatment with crizotinib or ceritinib.   
Tumor-bearing animals were treated with either crizotinib (100mg/kg/day, orally) or ceritinib 
(100mg/kg/day, orally) for seven days before animal sacrifice and harvesting of tumor tissue 
samples.  (A) MRI volumetric measurements were undertaken on day 0 and day 7, and 
percentage change in volume calculated.  (B) Representative abdominal MR images of 
matched coronal sections from individual animals included in the study on day 0 and day 7.  
Red dotted line indicates tumor.  Quantitation of phospho-Y1586 ALK (C) and total ALK 
(D) from Th-ALKF1174L/MYCN tumor lysates using immunoassays.  Mean±SD from 3 
technical repeats, with corresponding immunoblots shown directly underneath.  Arrow 
indicates phospho-Y1586 ALK band of interest at 220KDa.  (E) Phosphorylated ALK / total 
ALK ratios in tumor lysates calculated from immunoassay signals and normalized to mean of 
vehicle controls (normalized P/T ratio).  
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